OR WAIT null SECS
5 Allergy Headlines You Missed in November
This month in review spotlights 5 top allergy headlines published in November, including late-breaking data at ACAAI 2025.
November was an active month in allergy, immunology, and dermatology, with numerous pivotal data presentations at the 2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida. From late-breaking studies on rapid-acting pediatric sublingual epinephrine to benralizumab for HES, the research showcased advances in treatment and allergy prevention strategies.
This month in review captures the 5 top allergy headlines from last month.
Phase 3 Data Presented at ACAAI
Over 70% of Toddlers Tolerate 3 to 4 Peanut Kernels 3 Years After Peanut Patch
New data from the open-label extension of the phase 3 EPITOPE trial show that the Viaskin Peanut Patch builds lasting peanut tolerance in toddlers. After 3 years of treatment, 71% of children could tolerate the equivalent of 3 - 4 peanut kernels, an improvement from 63% after 1 year. Nearly half tolerated even higher amounts.
No treatment-emergent anaphylaxis occurred in year 3, and skin irritation became less frequent. Symptoms during food challenges also grew milder over time. Investigators say early epicutaneous immunotherapy may help modify the course of peanut allergy, offering families a safe alternative to oral immunotherapy.
Phase 3 LIBERTY AIMS results presented at ACAAI 2025 show dupilumab significantly improves outcomes for patients with allergic fungal rhinosinusitis (AFRS), a difficult CRSwNP subtype typically excluded from biologic trials. In the year-long study of 62 patients, dupilumab reduced sinus opacification by 50% versus 9.8% with placebo and led to major improvements in nasal congestion and polyp size at weeks 24 and 52. Patients on dupilumab had a 92% lower risk of requiring oral corticosteroids or surgery. Safety was consistent with prior studies. If approved, dupilumab could offer a targeted, steroid-sparing option for this challenging condition.
Benralizumab Reduces HES Flare in Phase 3 Trial, With Princess Ogbogu, MD
Phase 3 NATRON data presented at ACAAI 2025 show benralizumab significantly reduces flares and fatigue in patients with hypereosinophilic syndrome (HES). In a randomized, double-blind trial of patients aged ≥ 12 years with active, steroid-responsive HES, benralizumab, an IL-5 receptor–targeting monoclonal antibody, prolonged time to first flare and lowered annualized flare rates compared with placebo. Improvements in fatigue appeared by week 4 and persisted through week 24. Safety outcomes were consistent with prior studies, with common events including headache and respiratory infections. These findings highlight benralizumab as a promising long-term, targeted therapy for eosinophil-driven HES.
More Coverage from ACAAI
ACAAI 2025 Recap: Data Readouts to Know
ACAAI 2025 featured late-breaking and phase 3 studies across allergy and immunology, including rapid-acting pediatric sublingual epinephrine, benralizumab for HES flares, sebetralstat for on-demand HAE treatment, povorcitinib for CSU, dupilumab for allergic fungal rhinosinusitis, and tapinarof cream for pediatric atopic dermatitis.
Even more coverage here: https://www.hcplive.com/conference/acaai
Other Interviews You May Have Missed Last Month
ICD-10, CPT Updates for 2025: What Allergists Need to Know, With Gary Gross, MD
Gary N. Gross, MD, outlined key 2025 ICD-10 and CPT updates relevant for allergists. New ICD-10 codes now capture progress in food allergy desensitization, including baked egg or milk challenges, helping personalize long-term treatment. CPT codes remain largely consistent with 2024, but clarifications on medical decision-making and prescription management emphasize accurate documentation. Gross advised careful record-keeping, proper use of modifier 25 for same-day E/M and procedures, and tracking payer-specific coding requirements to prevent claim denials. He also encouraged allergists to review 2026 updates early, noting telehealth coding continues to evolve, requiring ongoing attention for compliance and reimbursement.
New data show a significant decline in peanut allergy rates, highlighting the success of early introduction guidelines. Stanislaw J. Gabryszewski, MD, PhD, explained that the 2015 LEAP study and 2017 guideline updates, which encouraged early peanut introduction for infants at varying risk levels, contributed to real-world reductions of 27% and 43%, respectively. The findings support early, developmentally appropriate introduction of allergenic foods as an effective prevention strategy.
